Document is current

Article History

Received: 11 July 2021

Accepted: 19 January 2022

First Online: 15 February 2022

Declarations

:

: The authors declared no competing interests in this section.

: The phase Ia/Ib trial conducted in Australia (NCT03352531) was approved by the local ethics committee of Bellberry Human Research Ethics Committee, Australia. The phase Ib/II trial conducted in China (NCT04172506) was approved by the local ethics committee of The First Affiliated Hospital of Zhejiang University School of Medicine, China. All patients signed an informed consent form during the initial visit. The trial registration number was NCT03352531 and NCT04172506.

: All authors agreed to publish this paper.